Acquired resistance to chloroquine in human CEM T cells is mediated by multidrug resistance-associated protein 1 and provokes high levels of cross-resistance to glucocorticoids

Arthritis and Rheumatism

Volumn 54, Issue 2, 2006, Pages 557-568

  Oerlemans, Ruud ^a   Van Der Heijden, Joost ^a   Vink, Josefien ^a   Dijkmans, Ben A C ^a   Kaspers, Gertjan J L ^a   Lems, Willem F ^a   Scheffer, George L ^a   Ifergan, Ilan ^b   Scheper, Rik J ^a   Cloos, Jacqueline ^a   Assaraf, Yehuda G ^b   Jansen, Gerrit ^a  

^a VU UNIVERSITY MEDICAL CENTER   (Netherlands)

^b TECHNION ISRAEL INSTITUTE OF TECHNOLOGY   (Israel)

Author keywords

[No Author keywords available]

Indexed keywords

ADENOSINE TRIPHOSPHATE; CHEMOKINE; CHLOROQUINE; CYCLIC AMP DEPENDENT PROTEIN KINASE; CYCLOSPORIN A; CYTOKINE; DEXAMETHASONE; DISEASE MODIFYING ANTIRHEUMATIC DRUG; FORSKOLIN; GLUCOCORTICOID; INTERLEUKIN 8; LEFLUNOMIDE; METHOTREXATE; MULTIDRUG RESISTANCE PROTEIN 1; PROBENECID; SALAZOSULFAPYRIDINE; TUMOR NECROSIS FACTOR ALPHA; VERLUKAST;

ARTICLE; CANCER CELL CULTURE; CONTROLLED STUDY; CROSS RESISTANCE; CYTOKINE RELEASE; DRUG EFFICACY; DRUG INHIBITION; DRUG RESISTANCE; DRUG SENSITIVITY; HUMAN; HUMAN CELL; IN VITRO STUDY; LONG TERM EXPOSURE; PRIORITY JOURNAL; RHEUMATOID ARTHRITIS; T LYMPHOCYTE; WESTERN BLOTTING;

ANTIRHEUMATIC AGENTS; BLOTTING, WESTERN; CELL LINE; CHLOROQUINE; DOSE-RESPONSE RELATIONSHIP, DRUG; DRUG RESISTANCE, MULTIPLE; GLUCOCORTICOIDS; HUMANS; MULTIDRUG RESISTANCE-ASSOCIATED PROTEINS; T-LYMPHOCYTES;

EID: 32444450168     PISSN: 00043591     EISSN: None     Source Type: Journal    
DOI: 10.1002/art.21569     Document Type: Article

References (50)

1. O'Dell JR. Therapeutic strategies for rheumatoid arthritis. N Engl J Med 2004;350:2591-602.
2. Smolen JS, Steiner G. Therapeutic strategies for rheumatoid arthritis. Nat Rev Drug Discov 2003;2:473-88.
3. Nurmohamed MT, Dijkmans BA. Efficacy, tolerability and cost effectiveness of disease-modifying antirheumatic drugs and biologic agents in rheumatoid arthritis. Drugs 2005;65:661-94.
4. Mottonen T, Hannonen P, Leirisalo-Repo M, Nissila M, Kautiainen H, Korpela M, et al, and the FIN-RACo trial group. Comparison of combination therapy with single-drug therapy in early rheumatoid arthritis: a randomised trial. Lancet 1999;353:1568-73.
5. Wolfe F. The epidemiology of drug treatment failure in rheumatoid arthritis. Baillieres Clin Rheumatol 1995;9:619-32.
6. Maetzel A, Wong A, Strand V, Tugwell P, Wells G, Bombardier C. Meta-analysis of treatment termination rates among rheumatoid arthritis patients receiving disease-modifying anti-rheumatic drugs. Rheumatology (Oxford) 2000;39:975-81.
7. Bradshaw DM, Arceci RJ. Clinical relevance of transmembrane drug efflux as a mechanism of multidrug resistance. J Clin Oncol 1998;16:3674-90.
8. Djimde A, Doumbo OK, Cortese JF, Kayentao K, Doumbo S, Diourte Y, et al. A molecular marker for chloroquine-resistant falciparum malaria. N Engl J Med 2001;344:257-63.
9. Borst P, Oude Elferink RP. Mammalian ABC transporters in health and disease. Annu Rev Biochem 2002;71:537-92.
10. Jansen G, Scheper RJ, Dijkmans BA. Multidrug resistance proteins in rheumatoid arthritis, role in disease-modifying antirheumatic drug efficacy and inflammatory processes: an overview. Scand J Rheumatol 2003;32:325-36.
11. Fathy N, Furst DE. Combination therapy for autoimmune diseases: the rheumatoid arthritis model. Springer Semin Immunopathol 2001;23:5-26.
12. Dijkmans BA, van den Borne BE, Landewe RB, Miltenburg AM, Verweij CL, Breedveld FC. Chloroquine combined with cyclosporine in rheumatoid arthritis: more than the addition of 2 drugs alone. J Rheumatol Suppl 1996;44:61-3.
13. O'Dell JR, Leff R, Paulsen G, Haire C, Mallek J, Eckhoff PJ, et al. Treatment of rheumatoid arthritis with methotrexate and hydroxychloroquine, methotrexate and sulfasalazine, or a combination of the three medications: results of a two-year, randomized, double-blind, placebo-controlled trial. Arthritis Rheum 2002;46:1164-70.
14. Mauritz R, Bekkenk MW, Rots MG, Pieters R, Mini E, van Zantwijk CH, et al. Ex vivo activity of methotrexate versus novel antifolate inhibitors of dihydrofolate reductase and thymidylate synthase against childhood leukemia cells. Clin Cancer Res 1998;4:2399-410.
15. Van der Heijden J, de Jong MC, Dijkmans BA, Lems WF, Oerlemans R, Kathmann GA, et al. Development of sulphasalazine resistance in human T cells induces expression of the multidrug resistance transporter ABCG2 (BCRP) and augmented production of TNFα. Ann Rheum Dis 2004;63:138-43.
16. Scheffer GL, Kool M, Heijn M, de Haas M, Pijnenborg AC, Wijnholds J, et al. Specific detection of multidrug resistance proteins MRP1, MRP2, MRP3, MRP5, and MDR3 P-glycoprotein with a panel of monoclonal antibodies. Cancer Res 2000;60:5269-77.
17. Haarman EG, Kaspers GJ, Pieters R, Rottier MM, den Boer ML, Janka-Schaub GE, et al. In vitro glucocorticoid resistance in childhood leukemia correlates with receptor affinity determined at 37 degrees C, but not with affinity determined at room temperature. Leukemia 2002;16:1882-4.
18. Macfarlane DE, Manzel L. Antagonism of immunostimulatory CpG-oligodeoxynucleotides by quinacrine, chloroquine, and structurally related compounds. J Immunol 1998;160:1122-31.
19. Zamora JM, Pearce HL, Beck WT. Physical-chemical properties shared by compounds that modulate multidrug resistance in human leukemic cells. Mol Pharmacol 1988;33:454-62.
20. Vezmar M, Georges E. Direct binding of chloroquine to the multidrug resistance protein (MRP): possible role for MRP in chloroquine drug transport and resistance in tumor cells. Biochem Pharmacol 1998;56:733-42.
21. Cardelli JA, Richardson J, Miears D. Role of acidic intracellular compartments in the biosynthesis of Dictyostelium lysosomal enzymes: the weak bases ammonium chloride and chloroquine differentially affect proteolytic processing and sorting. J Biol Chem 1989;264:3454-63.
22. Jansen G, Barr H, Kathmann I, Bunni MA, Priest DG, Noordhuis P, et al. Multiple mechanisms of resistance to polyglutamatable and lipophilic antifolates in mammalian cells: role of increased folylpolyglutamylation, expanded folate pools, and intralysosomal drug sequestration. Mol Pharmacol 1999;55:761-9.
23. Hooijberg JH, Broxterman HJ, Kool M, Assaraf YG, Peters GJ, Noordhuis P, et al. Antifolate resistance mediated by the multidrug resistance proteins MRP1 and MRP2. Cancer Res 1999;59:2532-5.
24. Kofler R, Schmidt S, Kofler A, Ausserlechner MJ. Resistance to glucocorticoid-induced apoptosis in lymphoblastic leukemia. J Endocrinol 2003;178:19-27.
25. Smoak KA, Cidlowski JA. Mechanisms of glucocorticoid receptor signaling during inflammation. Mech Ageing Dev 2004;125:697-706.
26. Salmon SE, Dalton WS. Relevance of multidrug resistance to rheumatoid arthritis: development of a new therapeutic hypothesis. J Rheumatol Suppl 1996;44:97-101.
27. Morgan C, Lunt M, Brightwell H, Bradburn P, Fallow W, Lay M, et al. Contribution of patient related differences to multidrug resistance in rheumatoid arthritis. Ann Rheum Dis 2003;62:15-9.
28. Aletaha D, Smolen JS. Effectiveness profiles and dose dependent retention of traditional disease modifying antirheumatic drugs for rheumatoid arthritis: an observational study. J Rheumatol 2002;29:1631-8.
29. Ambudkar SV, Dey S, Hrycyna CA, Ramachandra M, Pastan I, Gottesman MM. Biochemical, cellular, and pharmacological aspects of the multidrug transporter. Annu Rev Pharmacol Toxicol 1999;39:361-98.
30. Munster T, Gibbs JP, Shen D, Baethge BA, Botstein GR, Caldwell J, et al. Hydroxychloroquine concentration-response relationships in patients with rheumatoid arthritis. Arthritis Rheum 2002;46:1460-9.
31. Haarman EG, Kaspers GJ, Veerman AJ. Glucocorticoid resistance in childhood leukaemia: mechanisms and modulation. Br J Haematol 2003;120:919-29.
32. Buttgereit F, Straub RH, Wehling M, Burmester GR. Glucocorticoids in the treatment of rheumatic diseases: an update on the mechanisms of action [review]. Arthritis Rheum 2004;50:3408-17.
33. Chikanza IC, Kozaci DL. Corticosteroid resistance in rheumatoid arthritis: molecular and cellular perspectives. Rheumatology (Oxford) 2004;43:1337-45.
34. Arnal C, Piette JC, Leone J, Taillan B, Hachulla E, Roudot-Thoraval F, et al. Treatment of severe immune thrombocytopenia associated with systemic lupus erythematosus: 59 cases. J Rheumatol 2002;29:75-83.
35. Medh RD, Saeed MF, Johnson BH, Thompson EB. Resistance of human leukemic CEM-C1 cells is overcome by synergism between glucocorticoid and protein kinase A pathways: correlation with c-Myc suppression. Cancer Res 1998;58:3684-93.
36. Weber SM, Levitz SM. Chloroquine interferes with lipopolysaccharide- induced TNF-α gene expression by a nonlysosomotropic mechanism. J Immunol 2000;165:1534-40.
37. Weber SM, Chen JM, Levitz SM. Inhibition of mitogen-activated protein kinase signaling by chloroquine. J Immunol 2002;168:5303-9.
38. Yudoh K, Matsuno H, Nakazawa F, Yonezawa T, Kimura T. Increased expression of multidrug resistance of P-glycoprotein on Th1 cells correlates with drug resistance in rheumatoid arthritis. Arthritis Rheum 1999;42:2014-5.
39. Maillefert JF, Maynadie M, Tebib JG, Aho S, Walker P, Chatard C, et al. Expression of the multidrug resistance glycoprotein 170 in the peripheral blood lymphocytes of rheumatoid arthritis patients: the percentage of lymphocytes expressing glycoprotein 170 is increased in patients treated with prednisolone. Br J Rheumatol 1996;35:430-5.
40. Llorente L, Richaud-Patin Y, Diaz-Borjon A, Alvarado DL, Jakez-Ocampo J, De La Fuente H, et al. Multidrug resistance-1 (MDR-1) in rheumatic autoimmune disorders. I. Increased P-glycoprotein activity in lymphocytes from rheumatoid arthritis patients might influence disease outcome. Joint Bone Spine 2000;67:30-9.
41. Rahman P, Hefferton D, Robb D. Increased MDR1 P-glycoprotein expression in methotrexate resistance: comment on the article by Yudoh et al [letter]. Arthritis Rheum 2000;43:1662.
42. Bentires-Alj M, Barbu V, Fillet M, Chariot A, Relic B, Jacobs N, et al. NF-κB transcription factor induces drug resistance through MDR1 expression in cancer cells. Oncogene 2003;22:90-7.
43. Stein U, Walther W, Laurencot CM, Scheffer GL, Scheper RJ, Shoemaker RH. Tumor necrosis factor-α and expression of the multidrug resistance-associated genes LRP and MRP. J Natl Cancer Inst 1997;89:807-13.
44. Van der Heijden J, de Jong MC, Dijkmans BA, Lems WF, Oerlemans R, Kathmann GA, et al. Acquired resistance of human T cells to sulphasalazine: stability of the resistant phenotype and sensitivity to non-related DMARDs. Ann Rheum Dis 2004;63:131-7.
45. Randolph GJ. Dendritic cell migration to lymph nodes: cytokines, chemokines, and lipid mediators. Semin Immunol 2001;13:267-74.
46. Robbiani DF, Finch RA, Jager D, Muller WA, Sartorelli AC, Randolph GJ. The leukotriene C(4) transporter MRP1 regulates CCL19 (MIP-3β, ELC)-dependent mobilization of dendritic cells to lymph nodes. Cell 2000;103:757-68.
47. Wijnholds J, Evers R, van Leusden MR, Mol CA, Zaman GJ, Mayer U, et al. Increased sensitivity to anticancer drugs and decreased inflammatory response in mice lacking the multidrug resistance-associated protein. Nat Med 1997;3:1275-9.
48. Laupeze B, Amiot L, Payen L, Drenou B, Grosset JM, Lehne G, et al. Multidrug resistance protein (MRP) activity in normal mature leukocytes and CD34-positive hematopoietic cells from peripheral blood. Life Sci 2001;68:1323-31.
49. Jansen G, van der Heijden J, Oerlemans R, Lems WF, Ifergan I, Scheper RJ, et al. Sulfasalazine is a potent inhibitor of the reduced folate carrier: implications for combination therapies with methotrexate in rheumatoid arthritis. Arthritis Rheum 2004;50:2130-9.
50. Oerlemans R, Dijkmans BA, van der Heijden JW, Lems WF, Reurs AW, Scheffer GL, et al. Differential expression of multidrug resistance-related proteins on monocyte-derived macrophages from rheumatoid arthritis patients. Arthritis Res Ther 2005;7 Suppl 1:S32.